ACAD vs LLY
ACADIA Pharmaceuticals Inc. vs Eli Lilly and Company — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
67
Buy
VS
LLY
Eli Lilly and Company
56
Buy
| Metric | ACAD | LLY |
|---|
| AI Score |
67
|
56
|
| Price |
$30.58
|
$1,238.96
|
| P/E Ratio |
13.18×
|
41.81×
|
| ROE |
31.9%
|
77.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
84.0%
|
| Debt / Equity |
0.06×
|
1.62×
|
| Dividend Yield |
0.0%
|
0.5%
|
| RSI (14) |
61.2
|
59.0
|
| Beta |
0.845
|
0.506
|
| Expected Upside |
—
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus LLY.
ACAD leads by 11 points.
ACAD scores 67/100 (Buy) versus LLY at 56/100 (Buy).
ACAD Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- P/E of 12.9 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- Bollinger bandwidth of 22.8% signals elevated volatility — Risk
LLY Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 49.6% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 1.60) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 92.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 49.6% YoY -- genuine top-line momentum — Growth
- EPS growing 94.6% YoY — Growth
Bear Case
- P/E of 43.2 is expensive by classic value standards — Value
- Price-to-book of 38.3x prices in significant intangible value — Value
- Debt-to-equity of 1.60 adds balance-sheet risk to the value case — Value